On Thursday, Humana Inc (NYSE:HUM)’s shares declined -0.21% to $213.16.
More than 50 percent of health care financial executives have seen positive return on investment (ROI) from value-based payment models, according to a survey conducted by the Healthcare Financial Administration Association (HFMA) and sponsored by Humana Inc. (HUM).
Key findings of the HFMA survey comprised of:
- Positive Return on Investment (ROI)—More than 50 percent of the executives surveyed report their systems have achieved positive ROI from value-based payment models.
- Data Analytics a Key Enabler—Data competencies ranked highest in likelihood of enabling success in the organization’s abilities to take on risk-based arrangements.
- NoteworthyGaps in Interoperability—Only 16 percent of executives believe that their organization presently is highly capable when it comes to interoperability; 68 percent of executives anticipate interoperability capabilities will be extremely important in three years.
- Need for Change—Respondents expect in three years that 30 to 70 percent of their commercial payments will comprise value-based mechanisms.
Humana Inc., together with its auxiliaries, operates as a health and well-being company. The company operates through three segments: Retail, Employer Group, and Healthcare Services. The Retail segment provides Medicare and commercial fully-insured medical and specialty health insurance benefits, counting dental, vision, and other supplemental health and financial protection products directly to individuals.
Puma Biotechnology Inc (NYSE:PBYI)’s shares dropped -1.92% to $144.09.
Puma Biotechnology Inc (PBYI) declared that Alan H. Auerbach, Chairman, Chief Executive Officer, President and Founder of Puma, will provide an overview of the Company at 9:20 a.m. PDT on Wednesday, June 10, at the Goldman Sachs 36th Annual Global Healthcare Conference. The conference will be held at Terranea in Rancho Palos Verdes, California.
Puma Biotechnology, Inc., a development stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of products for the treatment of various forms of cancer. Its drug candidates comprise PB272 (neratinib (oral)) for the treatment of advanced breast cancer patients, non-small cell lung cancer patients, and patients with HER2 mutation-positive solid tumors; and PB272 (neratinib (intravenous)) for the treatment of advanced cancer patients.
At the end of Thursday’s trade, T. Rowe Price Group Inc (NASDAQ:TROW)‘s shares dipped -0.96% to $79.20.
- Rowe Price Group Inc (TROW) declared that it closed its Health Sciences Fund and similar portfolios for institutional clients at 4 p.m. ET recently. The decision to close the fund was made to maintain the integrity of the fund’s investment strategy and to protect the interests of existing shareholders. While the fund is closed to new investors, it will continue to accept additional investments from existing shareholders and from participants in an employer-sponsored retirement plan for which the fund serves as an investment option. New IRAs may also be opened through a direct rollover from an employer-sponsored retirement plan.
- Rowe Price Health Sciences Fund, which launched on December 29, 1995, seeks long-term capital appreciation from the stocks of companies involved in health care, medicine, and life sciences. It has been managed since February 15, 2013, by Taymour Tamaddon, who has been an investment professional at T. Rowe Price since 2004. The Health Sciences Fund received an Overall Morningstar RatingTM of five stars as of April 30, 2015.1 Its ticker symbol is PRHSX.
This is the first time the Health Sciences Fund has closed to new investors. The pace of inflows into the fund has raised dramatically in recent years. With $14.8 billion in total assets in the Health Sciences Strategy as of April 30, 2015–counting $14.1 billion in the Health Sciences Fund–assets have risen by $5.9 billion since the end of 2013. The strategy had nearly $1.8 billion of inflows during that time, counting $1.1 billion this year through April 30. Closing the fund to new investors will assist ensure that additional inflows do not overwhelm the portfolio manager’s ability to meet the fund’s investment objective.
- Rowe Price Group, Inc. is a publicly owned asset administration holding company. The firm provides its services to individuals, institutional investors, retirement plans, financial intermediaries, and institutions. It invests in the public equity and fixed income markets across the globe. It also invests in alternative markets, counting currency markets. The firm employs fundamental and quantitative analysis with a bottom-up approach. It utilizes in-house and external research to make its investments.
Bill Barrett Corporation (NYSE:BBG), ended its Thursday’s trading session with 0.11% gain, and closed at $9.11.
Bill Barrett Corporation (BBG) has shown underwhelming performance over the last one year while growing strongly over the last month. Bill Barrett Corp.’s price momentum over the last month, at 15.95% has been better than that over the last year, which was -58.97%. Also from a peer group perspective, Bill Barrett Corp. has performed better, since the peer group performance was 0.75% over the last month.
Company Snapshot
- Contrast to peers, relative underperformance over the last year is in contrast with the more recent outperformance.
- Bill Barrett Corporation trades at a lower Price/Book multiple (0.50) than its peer median (0.99).
- The market anticipates faster earnings growth from BBG-US than from its peers and also a turnaround in its current ROE.
- BBG-US ‘s relatively low net margins and poor asset turns suggest a problematic operating strategy.
- Changes in annual earnings are in line with its chosen peers but lags in terms of revenue, implying the company is cost conscious and selective about spending for growth.
- BBG-US ‘s return on assets presently and over the past five years has trailed the peer median and suggests the company might be operationally challenged relative to its peers.
- The company’s relatively low gross and pre-tax margins suggest a non-differentiated product portfolio and not much control on operating costs relative to peers.
Share Price Performance
Contrast to peers, relative underperformance over the last year is in contrast with the more recent outperformance.
BBG-US ‘s share price performance of -58.97% over the last 12 months is below its peer median but its 30-day trend in share price performance of 15.95% is better than the peer median. This recent rising stock price may herald a change in relative share price performance.
Bill Barrett Corporation, an independent energy company, acquires, explores for, and develops oil and natural gas resources in the United States. It primarily holds interests in the Denver-Julesburg basin, the Uinta oil program in the Uinta Basin, and the Gibson Gulch area in the Piceance basin in the Rocky Mountain region of the United States.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
